Therapeutic Strategies for Fibrotic Diseases
AlphaScreen® SureFire® pERK and HTRF® cGMP kits were used to better u...
NASH / Fibrosis
Nonalcoholic fatty liver disease (NAFLD) remains a major cause of liver-related morbidity and mortality worldwide. This complex disease is associated with obesity, diabetes, and dyslipidemia, but has been increasingly recognized in normal-weight individuals. Explore our articles, news, literature reviews, tips, and more on NASH research.
PIIINP and liver fibrosis severity in children wit...
Discover how PIIINP ELISA test assesses NAFLD staging in children
Effect of Peritoneal Dialysis on Serum Fibrosis Bi...
Measuring circulating cardiac fibrosis markers in patients treated for h...
A Novel Interacting Protein SERP1 Regulates the N-...
SERP1: a new GLP-1 receptor interactor
Collagen Biomarkers and Incidence of New Onset of ...
Investigation of atrial fibrosis in the pathogenesis of atrial fibrillat...
PIIINP measurements for the detection of liver fib...
A marker for monitoring liver fibrosis in MTX-treated patients
Urinary procollagen III aminoterminal propeptide a...
A marker for monitoring kidney fibrosis risk in children with SFK
Procollagen-III peptide identifies adipose tissue-...
A marker for monitoring liver fibro-inflammation in Type 2 diabetes pati...
NASH - Fibrosis symposium
Exclusive symposium on NASH/Fibrosis challenges featuring key opinion le...